Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling

被引:33
作者
Kim, Jieun [1 ]
Lee, Hyun-ju [1 ]
Park, Jin-Hee [1 ,2 ]
Cha, Byung-Yoon [3 ]
Hoe, Hyang-Sook [1 ,2 ]
机构
[1] Korea Brain Res Inst KBRI, Dept Neural Dev & Dis, 61 Cheomdan Ro, Daegu 41062, South Korea
[2] Daegu Gyeongbuk Inst Sci & Technol, Dept Brain & Cognit Sci, Daegu 42988, South Korea
[3] PharmacoRex Co Ltd, 20 Techno 1 Ro, Daejeon 34016, South Korea
基金
新加坡国家研究基金会;
关键词
Nilotinib; LPS; SOD2; STAT3; p38; Microglia; Cognitive function; TYROSINE KINASE INHIBITOR; MEMORY IMPAIRMENT; OXIDATIVE-STRESS; MICROGLIA; INFLAMMATION; ACTIVATION; INTERLEUKIN-1-BETA; IMMUNOREACTIVITY; DISEASE;
D O I
10.1186/s12974-022-02549-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background In chronic myelogenous leukemia, reciprocal translocation between chromosome 9 and chromosome 22 generates a chimeric protein, Bcr-Abl, that leads to hyperactivity of tyrosine kinase-linked signaling transduction. The therapeutic agent nilotinib inhibits Bcr-Abl/DDR1 and can cross the blood-brain barrier, but its potential impact on neuroinflammatory responses and cognitive function has not been studied in detail. Methods The effects of nilotinib in vitro and in vivo were assessed by a combination of RT-PCR, real-time PCR, western blotting, ELISA, immunostaining, and/or subcellular fractionation. In the in vitro experiments, the effects of 200 ng/mL LPS or PBS on BV2 microglial cells, primary microglia or primary astrocytes pre- or post-treated with 5 mu M nilotinib or vehicle were evaluated. The in vivo experiments involved wild-type mice administered a 7-day course of daily injections with 20 mg/kg nilotinib (i.p.) or vehicle before injection with 10 mg/kg LPS (i.p.) or PBS. Results In BV2 microglial cells, pre- and post-treatment with nilotinib altered LPS-induced proinflammatory/anti-inflammatory cytokine mRNA levels by suppressing AKT/P38/SOD2 signaling. Nilotinib treatment also significantly downregulated LPS-stimulated proinflammatory cytokine levels in primary microglia and primary astrocytes by altering P38/STAT3 signaling. Experiments in wild-type mice showed that nilotinib administration affected LPS-mediated microglial/astroglial activation in a brain region-specific manner in vivo. In addition, nilotinib significantly reduced proinflammatory cytokine IL-1 beta, IL-6 and COX-2 levels and P38/STAT3 signaling in the brain in LPS-treated wild-type mice. Importantly, nilotinib treatment rescued LPS-mediated spatial working memory impairment and cortical dendritic spine number in wild-type mice. Conclusions Our results indicate that nilotinib can modulate neuroinflammatory responses and cognitive function in LPS-stimulated wild-type mice.
引用
收藏
页数:28
相关论文
共 60 条
[1]   Neuroprotective effect of nilotinib on pentylenetetrazol-induced epilepsy in adult rat hippocampus: involvement of oxidative stress, autophagy, inflammation, and apoptosis [J].
Attia, Ghalia Mahfouz ;
Elmansy, Rasha Ahmed ;
Elsaed, Wael M. .
FOLIA NEUROPATHOLOGICA, 2019, 57 (02) :146-160
[2]   Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus [J].
Barrientos, RM ;
Higgins, EA ;
Sprunger, DB ;
Watkins, LR ;
Rudy, JW ;
Maier, SF .
BEHAVIOURAL BRAIN RESEARCH, 2002, 134 (1-2) :291-298
[3]   All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats [J].
Behairi, Nassima ;
Belkhelfa, Mourad ;
Rafa, Hayet ;
Labsi, Moussa ;
Deghbar, Nahla ;
Bouzid, Nora ;
Mesbah-Amroun, Hamida ;
Touil-Boukoffa, Chafia .
JOURNAL OF NEUROIMMUNOLOGY, 2016, 300 :21-29
[4]   Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide [J].
Beier, Eric E. ;
Neal, Matthew ;
Alam, Gelerah ;
Edler, Melissa ;
Wu, Long-Jun ;
Richardson, Jason R. .
NEUROBIOLOGY OF DISEASE, 2017, 108 :115-127
[5]   c-Abl-Mediated Tyrosine Phosphorylation of PARP1 Is Crucial for Expression of Proinflammatory Genes [J].
Bohio, Ameer Ali ;
Sattout, Aman ;
Wang, Ruoxi ;
Wang, Ke ;
Sah, Rajiv Kumar ;
Guo, Xiaolan ;
Zeng, Xianlu ;
Ke, Yueshuang ;
Boldogh, Istvan ;
Ba, Xueqing .
JOURNAL OF IMMUNOLOGY, 2019, 203 (06) :1521-1531
[6]   Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia [J].
Breccia, Massimo ;
Alimena, Giuliana .
LEUKEMIA RESEARCH, 2010, 34 (02) :129-134
[7]   Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia [J].
Claudiani, Simone ;
Apperley, Jane F. ;
Deplano, Simona ;
Khorashad, Jamshid ;
Foroni, Letizia ;
Palanicawandar, Renuka ;
Perry, Richard ;
Milojkovic, Dragana .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (11) :E480-E481
[8]   STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network [J].
Delyon, Julie ;
Chevret, Sylvie ;
Jouary, Thomas ;
Dalac, Sophie ;
Dalle, Stephane ;
Guillot, Bernard ;
Arnault, Jean-Philippe ;
Avril, Marie-Francoise ;
Bedane, Christophe ;
Bens, Guido ;
Pham-Ledard, Anne ;
Mansard, Sandrine ;
Grange, Florent ;
Machet, Laurent ;
Meyer, Nicolas ;
Legoupil, Delphine ;
Saiag, Philippe ;
Idir, Zakia ;
Renault, Victor ;
Deleuze, Jean-Francois ;
Hindie, Elif ;
Battistella, Maxime ;
Dumaz, Nicolas ;
Mourah, Samia ;
Lebbe, Celeste .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (01) :58-67
[9]   Inflammatory cytokines in vitro, production are associated with Alal6Val superoxide dismutase gene polymorphism of peripheral blood mononuclear cells [J].
Echart Montano, Marco Aurelio ;
Manica da Cruz, Ivana Beatrice ;
Medeiros Frescura Duarte, Marta Maria ;
Krewer, Cristina da Costa ;
de Ugalde Marques da Rocha, Maria Izabel ;
Manica-Cattani, Maria Fernanda ;
Antunes Soares, Felix Alexandre ;
Rosa, Guilherme ;
Maris, Angelica Francesca ;
Battiston, Francielle Garghetti ;
Trott, Alexis ;
Barrio Lera, Juan Pablo .
CYTOKINE, 2012, 60 (01) :30-33
[10]   Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in rats [J].
El-Agamy, Dina S. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2011, 253 (02) :153-160